Modern Slavery Act Statement

The UK Modern Slavery Act requires certain companies operating in the UK to publish a slavery and human trafficking statement and to publicly state what, if anything, it has done to prevent slavery and human trafficking in its business and supply chain. This statement constitutes Medpace’s statement for the fiscal year ending December 31, 2016.

Medpace strives to be a good corporate citizen and ascribes to the highest ethical standards. Medpace fully supports the eradication of slavery and human trafficking. All Medpace employees, officers and directors must agree to comply with the Medpace Code of Conduct and are required to take training about ethical behavior in all business dealings. Included in the training and the Code of Conduct are obligations for all employees, officers and directors to fully comply with all applicable laws.

Medpace’s Compliance Training states, “In keeping with the highest standards of ethical behavior required by Medpace’s Code of Conduct, Medpace prohibits slavery and human trafficking in its business. These practices are not tolerated in the recruiting of Medpace employees or clinical trial patients, or in the Medpace supply chain.”

Medpace is involved in many different aspects of clinical research providing services to the biotechnology, pharmaceutical and medical device industries. Medpace is not a supplier of goods and materials, but serves to assist companies in the development of safe and effective medical therapeutics. Medpace considers the risk of slavery or human trafficking in its supply chain or business to be low.

Clinical research is a highly regulated business sector that is subject to periodic compliance audits by regulatory authorities and its customer base, the sponsors of clinical research. Medpace also performs its own audits for compliance with the law. Medpace is fully committed to complying with all of the laws affecting its business, including the UK Modern Slavery Act.